136 related articles for article (PubMed ID: 30699067)
1. Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects.
Mindt S; Aida S; Merx K; Müller A; Gutting T; Hedtke M; Neumaier M; Hofheinz RD
Clin Chem Lab Med; 2019 Jun; 57(7):1012-1016. PubMed ID: 30699067
[TBL] [Abstract][Full Text] [Related]
2. Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
Wilhelm M; Mueller L; Miller MC; Link K; Holdenrieder S; Bertsch T; Kunzmann V; Stoetzer OJ; Suttmann I; Braess J; Birkmann J; Roessler M; Moritz B; Kraff S; Salamone SJ; Jaehde U
Clin Colorectal Cancer; 2016 Dec; 15(4):381-388. PubMed ID: 27256667
[TBL] [Abstract][Full Text] [Related]
3. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
Li M; Mindt S; Lück A; Hutzschenreuter U; Kollendt M; Lathan B; Zöller T; Frank-Gleich S; Lorentz C; Lamberti C; Sick C; Zingerle M; Tesch H; Stein W; Hebart H; Stosiek C; Sandner R; Fries S; Burkholder I; Hofheinz RD
ESMO Open; 2023 Apr; 8(2):101201. PubMed ID: 36965262
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Zhou X; Chang Y; Qian J; Shen C; Han J; Zhao H; Chang R
Med Sci Monit; 2021 Jul; 27():e929474. PubMed ID: 34330885
[TBL] [Abstract][Full Text] [Related]
5. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
6. How can we best monitor 5-FU administration to maximize benefit to risk ratio?
Goirand F; Lemaitre F; Launay M; Tron C; Chatelut E; Boyer JC; Bardou M; Schmitt A
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1303-1313. PubMed ID: 30451549
[TBL] [Abstract][Full Text] [Related]
7. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
8. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Kline CL; Sheikh HS; Scicchitano A; Gingrich R; Beachler C; Finnberg NK; Liao J; Sivik J; El-Deiry WS
Cancer Biol Ther; 2011 Oct; 12(7):557-68. PubMed ID: 21931273
[TBL] [Abstract][Full Text] [Related]
9. Correlation between pharmacokinetic parameters of 5-fluorouracil and related metabolites and adverse reactions in East-Asian patients with advanced colorectal cancer.
Tong Z; Cheng M; Yu Y; Yu J; Yin Y; Liu J; Zhang S; Jiang S; Dong M
Cancer Chemother Pharmacol; 2022 Mar; 89(3):323-330. PubMed ID: 35067736
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients.
Büchel B; Sistonen J; Joerger M; Aebi Y; Schürch S; Largiadèr CR
Clin Chem Lab Med; 2013 Aug; 51(8):1681-8. PubMed ID: 23412878
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of 5-fluorouracil.
Lee JJ; Beumer JH; Chu E
Cancer Chemother Pharmacol; 2016 Sep; 78(3):447-64. PubMed ID: 27217046
[TBL] [Abstract][Full Text] [Related]
12. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
14. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.
Moloney M; Faulkner D; Link E; Rischin D; Solomon B; Lim AM; Zalcberg JR; Jefford M; Michael M
Cancer Chemother Pharmacol; 2018 Nov; 82(5):865-876. PubMed ID: 30178115
[TBL] [Abstract][Full Text] [Related]
16. Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Matsumoto H; Okumura H; Murakami H; Kubota H; Higashida M; Tsuruta A; Tohyama K; Hirai T
Anticancer Res; 2015 Nov; 35(11):6193-9. PubMed ID: 26504050
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
[TBL] [Abstract][Full Text] [Related]
18. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Gamelin E; Boisdron-Celle M; Delva R; Regimbeau C; Cailleux PE; Alleaume C; Maillet ML; Goudier MJ; Sire M; Person-Joly MC; Maigre M; Maillart P; Fety R; Burtin P; Lortholary A; Dumesnil Y; Picon L; Geslin J; Gesta P; Danquechin-Dorval E; Larra F; Robert J
J Clin Oncol; 1998 Apr; 16(4):1470-8. PubMed ID: 9552054
[TBL] [Abstract][Full Text] [Related]
19. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.
Gusella M; Ferrazzi E; Ferrari M; Padrini R
Ther Drug Monit; 2002 Jun; 24(3):425-31. PubMed ID: 12021636
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]